Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ReShape Lifesciences Inc. (RSLS : NSDQ)
 
 • Company Description   
ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA.

Number of Employees: 47

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.82 Daily Weekly Monthly
20 Day Moving Average: 110,471 shares
Shares Outstanding: 18.65 (millions)
Market Capitalization: $15.21 (millions)
Beta: -0.60
52 Week High: $14.64
52 Week Low: $0.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.02% -13.31%
12 Week -23.02% -15.38%
Year To Date -50.24% -38.16%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1001 Calle Amanecer
-
San Clemente,CA 92673
USA
ph: 949-429-6680
fax: -
ir@reshapelifesci.com http://www.reshapelifesciences.com
 
 • General Corporate Information   
Officers
Barton P. Bandy - President and Chief Executive Officer
Dan W. Gladney - Chairman
Thomas Stankovich - Senior Vice President and Chief Financial Officer
Gary D. Blackford - Director
Lori McDougal - Director

Peer Information
ReShape Lifesciences Inc. (ABMD)
ReShape Lifesciences Inc. (DMDS)
ReShape Lifesciences Inc. (CPWY.)
ReShape Lifesciences Inc. (EQUR)
ReShape Lifesciences Inc. (ECIA)
ReShape Lifesciences Inc. (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 76090R101
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/23/22
Share - Related Items
Shares Outstanding: 18.65
Most Recent Split Date: 6.00 (0.33:1)
Beta: -0.60
Market Capitalization: $15.21 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.31
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 109.80%
vs. Previous Quarter: 104.17%
Sales Growth
vs. Year Ago Period: 5,050.82%
vs. Previous Quarter: 78,449.99%
ROE
03/31/22 - -
12/31/21 - -48.98
09/30/21 - -52.04
ROA
03/31/22 - -
12/31/21 - -33.58
09/30/21 - -31.79
Current Ratio
03/31/22 - -
12/31/21 - 4.13
09/30/21 - 3.64
Quick Ratio
03/31/22 - -
12/31/21 - 3.72
09/30/21 - 3.33
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -456.17
09/30/21 - -930.66
Book Value
03/31/22 - -
12/31/21 - 2.59
09/30/21 - 5.00
Inventory Turnover
03/31/22 - -
12/31/21 - 2.31
09/30/21 - 2.52
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©